Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
|Videos|June 29, 2017
Dr. Stratigos on the Prevention of Melanoma
Author(s)Alexander J. Stratigos, MD
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Advertisement
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Primary prevention is an approach that aims to reduce the exposure of UV radiation on human skin. The primary goals are to reduce the exposure through the use of sunscreen and protective clothing, explains Stratigos.
There is also prevention that aims to protect vulnerable populations such as children or outdoor workers. According to Stratigos, it is important for physicians to understand the early clues of skin cancer to better educate their patients on the importance of prevention.
<<<
Advertisement
Related to this article
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
4
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
5